Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach.
Review published in Current opinion in rheumatology (2023)
Abstract
PURPOSE OF REVIEW: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease that has morbid and sometimes devastating effects on patients and their families. This review will discuss the most recent international societal treatment guidelines and propose practical management algorithms for various APS sub-types. RECENT FINDINGS: APS represents a disease spectrum. Although thrombosis and pregnancy morbidities are traditional hallmarks of APS, a variety of extra-criteria clinical phenotypes can often be seen, which makes clinical management more challenging. Primary APS thrombosis prophylaxis should take a risk-stratified approach. Although vitamin K antagonists (VKAs) or heparin/low molecular weight heparin (LMWH) remain the preferred treatment for secondary APS thrombosis prophylaxis, some international society guidelines support the use of direct oral anticoagulants (DOACs) in certain circumstances. Careful monitoring and individualized obstetric care with the use of aspirin and heparin/LMWH will improve pregnancy outcomes among pregnant individuals with APS. Treatment of microvascular and catastrophic APS remains challenging. While the addition of various immunosuppressive agents is often utilized, further systemic evaluations of their use are warranted before definitive recommendations can be made. Several new therapeutic strategies are on the horizon that might enable more personalized and targeted APS management in the near future. SUMMARY: Although the knowledge of APS pathogenesis has grown in recent years, the management principles and strategies are largely unchanged. There is an unmet need for evaluating pharmacological agents, beyond anticoagulants, that target diverse thromboinflammatory pathways.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease that has morbid and sometimes devastating effects on patients and their families. This review will discuss the most recent international societal treatment guidelines and propose practical management algorithms for various APS sub-types.
Por qué esto importa para la hirudoterapia
Esta revisión analiza las guías de tratamiento de sociedades internacionales para el síndrome antifosfolipídico (SAF) y propone algoritmos prácticos de manejo para diversos subtipos de SAF, incluyendo la profilaxis de trombosis, el manejo del embarazo y el SAF catastrófico. Los antagonistas de la vitamina K y la heparina/HBPM siguen siendo los tratamientos preferidos para la profilaxis secundaria de trombosis, con algunas guías que respaldan el uso de anticoagulantes orales directos en casos seleccionados; la revisión también destaca necesidades no cubiertas de terapias dirigidas a las vías tromboinflamatorias más allá de los anticoagulantes. El resumen no menciona sanguijuelas, hirudoterapia, hirudina ni ninguna terapia derivada de sanguijuela. Su relevancia para ASH es inexistente, ya que la revisión se enfoca por completo en los enfoques farmacológicos convencionales y emergentes para el SAF sin abordar ninguna intervención relacionada con sanguijuelas.
Citación
Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach.
Ambati et al. · Current opinion in rheumatology, 2023
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: 18 de junio de 2026